Like every city, Houston experiences setbacks. The difference is Houston doesn’t dwell on them. It adapts, rebuilds and always comes back stronger. That’s exactly what the region is doing with biotech, an emerging sector where Houston is determined to lead.  The region’s economic development strategy shifted after losing Amazon’s HQ2 in 2019. Leaders doubled down on partnerships, long-term planning and industry diversification.  In 2022, there was another missed opportunity. A leading pharmaceutical company’s decision to choose North Carolina highlighted another critical gap in Houston – the need for a biotech workforce.   Rather than retreat, Houston responded with action. San Jacinto College (SJC) and Generation Park launched a bold partnership to build a biotech talent pipeline, ensuring the region is ready for the next big opportunity.  Learn more about Houston’s life sciences industry and how local colleges and businesses are working together to build the region’s biotech workforce.  SJC & Generation Park Partnership  Ryan McCord, McCord Development President and the visionary behind Generation Park, had long believed Houston could lead in life sciences. But as biotech investments flowed to other cities, it became clear: infrastructure alone wasn’t enough.  While Houston’s life sciences sector has grown steadily over the past decade— recording the second-highest employment growth rate among major markets from 2022 to 2023, according to CBRE’s 2025 Life Sciences Outlook—the region continued to face a shortage of technicians to support critical functions such as laboratory setup, data collection and research observation.  That’s when McCord turned to SJC, a proven leader in workforce development with a track record of building industry-aligned programs. Together, they launched the Center for Biotechnology, a workforce-first solution to close the talent gap and make Houston a top destination for biotech companies.  "San Jacinto College’s Biotechnology Center at Generation Park is the catalyst our region needs to fill the gap in our existing life science ecosystem and accelerate biomanufacturing in Houston,” said McCord in a news release.  Inside the Center for Biotechnology  Opening this summer, the Center for Biotechnology offers more than just textbook knowledge, it delivers hands-on training with industry-grade equipment. At its core is a pilot-scale bioprocessing plant where students will gain real-world experience using the same tools found in commercial facilities.   Click to expand To develop the curriculum, SJC partnered with the National Institute for Bioprocessing Research and Training (NIBRT), a global leader in biopharma education. That partnership makes the center the exclusive provider of NIBRT-licensed training in the southern U.S., and one of just six institutions worldwide with this distinction.  “Building on San Jacinto College’s established track record of working with industry to develop need-specific training and accreditation centers, the partnership with NIBRT represents an opportunity to train the workforce that Houston's biopharma industry needs to sustain its rapid growth,” said Brenda Hellyer, Chancellor of SJC, in a statement. “We also expect to contribute to the global market by training people eager to enter this growing industry from around the United States and beyond.”  The center also offers students exposure to emerging fields like cell and gene therapy. A regional advisory board of life sciences leaders will guide the curriculum to ensure it evolves with industry needs.  Strategic Location  The center is located within Generation Park, one of Houston’s fastest-growing innovation districts, and sits just steps away from BioHub Two, a 45-acre biomanufacturing campus currently under development. Once complete, BioHub Two will feature 500,000 square feet of state-of-the-art lab, office and cGMP manufacturing space, designed to attract life sciences companies to the region.   Click to expand What makes this proximity so powerful is the built-in connection between workforce development and industry growth. Companies moving into BioHub Two won’t just gain access to premier infrastructure, they’ll have a direct pipeline to trained, job-ready talent.  Spanning 4,300 acres, Generation Park is also home to leading institutions like Lone Star College and companies such as TechnipFMC and Apache Industrial Services. Beyond businesses, the district offers a great quality of life, surrounded by restaurants, shops, green space and residential options, all just a short drive from George Bush Intercontinental Airport and Port Houston.  Positioned for the Future  The partnership between SJC and Generation Park is more than a response to a missed opportunity – it’s a bold investment in Houston’s future. The Center for Biotechnology demonstrates how aligning education with industry needs can unlock long-term growth, strengthen the region’s talent pipeline, and position Houston as a national hub for life sciences innovation and biomanufacturing. 

Launching a biotech startup is one of the most difficult undertakings in science and business. For Sarah Hein, founder and CEO of March Biosciences, choosing Houston made all the difference.  While most early-stage companies struggle to navigate the so-called "valleys of death" — the critical and often underfunded stages between research breakthroughs and real-world treatments — March Biosciences found the support it needed to move fast and scale its innovation. Hein credits Houston’s robust life sciences ecosystem for making that possible – saying Houston is one of the few places where you can go from the lab to commercialization.   “Houston has unique infrastructure and opportunities that made building March Bio here an obvious choice—the scientific and medical expertise of the largest medical center in the world, the local talent pool from that medical center, and then partnership opportunities,” Hein told the Greater Houston Partnership.  Want to learn more about Houston’s life sciences and biotech ecosystem, join us at the 2025 BIO International Convention from June 16 - 19. From Research to a Life-Saving Therapy  March Bio was founded out of the Center for Cell and Gene Therapy (CAGT), a collaboration among Baylor College of Medicine (BCM), Houston Methodist and Texas Children’s Hospital. At the CAGT, March Bio worked with scientists to develop its lead therapy, MB-105, a CAR-T cell treatment targeting T-cell lymphoma and T-cell acute lymphoblastic leukemia, two aggressive cancers with limited treatment options.  CAR-T cell therapy involves collecting a patient’s own immune cells, engineering them to better recognize and attack cancer, and then reintroducing them into the body. Proximity to patients is essential for this personalized approach, and Houston’s concentration of clinical expertise makes it an ideal hub. As of mid-2024, the region hosted more than 2,200 active clinical trials, accounting for 11 percent of all trials in the U.S.  MB-105 showed a 44 percent patient response rate in Phase 1 trials at BCM. With that early success, March Bio turned to Houston’s ecosystem to accelerate its development.  Strategic Partnerships   In 2023, March Bio announced a strategic alliance with the CTMC, a joint effort between National Resilience and MD Anderson Cancer Center. CTMC provides biotech startups with comprehensive support, from development and manufacturing to regulatory guidance.   “Our close collaboration with MD Anderson Cancer Center provides access to leading regulatory expertise and one of the world's largest clinical trial programs, ensuring promising therapies reach patients faster,” Amy Hay, Chief Business Officer of CTMC, told the Partnership.  CTMC’s infrastructure enabled March Bio to grow without the financial burden of building its own facilities. “By taking on the heavy operational costs—housing the program in our 60,000 SF industrial-grade cGMP facility—CTMC enabled March to remain lean and focused on innovation,” she explained.   Fueling Growth Through Investment  Beyond research and partnerships, Houston offers the capital resources biotech companies need to grow, and March Biosciences has tapped into them at every stage of its journey.   The company secured early investment from the TMC Venture Fund and Portal Innovations, a venture capital firm that expanded to Houston in 2023 with the goal of supporting startups through funding, lab space and commercialization expertise.  “Portal’s investment in Houston is a mark of the growth and potential of the ecosystem,” said Hein. “March was their first biotech deal in Houston, and that early seed capital allowed us to get a lot of critical work done which set us up for our later financing success.”   March Bio’s momentum continued in 2024 with a $28.4 million Series A financing round, bringing its total amount raised to over $51 million.  Today, March Bio operates out of Portal’s labs at TMC Helix Park, where the company is currently conducting ongoing product development and early-stage discovery work.  State-level funding has been instrumental in fueling March Bio’s growth, with the Cancer Prevention and Research Institute of Texas (CPRIT) playing a significant role. March Bio was awarded a $13.4 million CPRIT grant to support its Phase 2 clinical trial. What sets CPRIT apart is that it is a state agency, established and funded by the State of Texas, making it one of the largest state-funded efforts against cancer. CPRIT has provided more than $3 billion in funding for cancer research and biotech innovation across Texas, contributing to a thriving life sciences ecosystem. With $6 billion dedicated to advancing cancer breakthroughs, CPRIT’s comprehensive approach supports the entire cancer care continuum while driving economic growth by attracting biotech companies and creating jobs. The company also received support from the Cancer Focus Fund, a MD Anderson–backed initiative that helps advance promising oncology therapies toward commercialization.  A Houston Success Story  Just four years after its founding in 2021, March Bio has advanced into Phase 2 trials and earned FDA orphan drug designation for MB-105. This designation is an important milestone that provides incentives such as tax credits and market exclusivity for rare disease treatments.  “Houston is home to the largest medical center in the world, with particular excellence in oncology, cardiovascular, and neurology research,” said Hein. “Patients come from all over the world to access the world class clinicians and novel clinical trials. Frankly, I think we simply have to keep doing the hard work of translating that leading research into the clinic, focusing on collaboration and growing our bench of talent, and the growth will follow.”  With its interconnected network of research institutions, capital resources, and strategic partners, Houston is proving to be a top destination for biotech companies. As the region continues investing in life sciences, more innovators like March Biosciences are expected to emerge, driving groundbreaking discoveries from concept to commercialization.